External validation of the prostascore model in patients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study.

The present study further confirms the role of prostascore in predicting the outcomes of patients with metastatic hormone-sensitive prostate cancer and also highlights its potential role in therapeutic decision-making.